Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности коррекции эндотелиальной дисфункции ингибиторами ангиотензинпревращающего фермента
Возможности коррекции эндотелиальной дисфункции ингибиторами ангиотензинпревращающего фермента
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Dzau VJ. Tissue rennin-angiotensin system in myocardial hypertrophy and failure. Arch Tern Med 1993; 153: 937–42.
2. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапии ингибиторами ангиотензинпревращающего фермента. Кардиология. 2001; 5: 100–4.
3. Ferrari R, Bachetti T, Guardigli G et al. Bradykinin and coronary artery disease. Eur Heart J 2000; 2 (Suppl. H): H14–H19.
4. Haefeli WE, Linder L, Lusher TF. Quinaprilat induces artepial vasodilation mediated by nitric oxide in humans. Hypertension 1997 Oct; 30 (4): 912–7.
5. Horing B, Arakawa N, Haussmann D et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98: 2842–8.
6. Anderson TJ, Elstein E, Haber H et al. Comparative stady of ACE-Inhibition, angiotensin II antagonism, and calsium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 2000; 35: 60–6.
7. Maclean D. Quinapril: а double-blind, placebo-controlled trial in essential hypertension. J Vascular Dis 1989; 4: 370–81.
8. Parra-Carrillo Jose Z, Olvera S, Verdjeo J et al. Multicentric study of quinapril, an angiotensin converting enzyme inhibitor, in the treatment of mild to moderate essential hypertension. Curr Ther Res 1992; 51: 185–95.
9. Wadworth AN, Brogden RN. Quanapril: a revive of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991; 41 (3): 378–99.
10. Parageorgiou A, Karayannis A, Athyros V et al. A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug invest 1994; 7 (1): 396–404.
11. Romero R, Castellote Е, Ocon J et al. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8.
12. Ienz Т, Schulte К-L, Wagner В et al. Quinapril, hydrochlorothiazide, and combination in patients with moderate со severe hypertension. Eur Heart J 1994; 15: 940–6.
13. Hausberg М. Angiotensin converting enzyme inhibitor versus beta- blocker for treatment of hypertension. 17'" scientific meeting ог 1йе international society of hypertension. 1998; 24.16.
14. Parageotgiou А, Karayiannts A, Athutos V et al. A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug Invest 1994; 7: 13–7.
15. Nakajima Т, Yamda Т, Setoguchi М. Quinapril provides more potent inhibition of tissue АСЕ than enalapril. J Cardiovasc Pharmacol 1992; 19: 102–7.
16. Kannel WВ. In: Left ventricular hypertrophy and regression. London: Messerrli 1992; 359: 1600–3.
17. Franz I-W, Tonnesmann U, Muller JF. Time course of complete regression of left ventricular hypertrophy during long-term antihypertensive therapy with АСЕ inhibitors. 8-th european meeting on hypertension. 1997; 100.
18. Clroux J. Endothelium: а new target for cardiovascular therapeutics. J Am Coll Cardiol 2000; 1: 67–70.
19. Мартынов А.И., Гороховская Г.Н. и др. Перспективы медикаментозного лечения эндотелиальной дисфункции. Фарматека. 2005; 9: 31–4.
20. Volkova N et al. Efficacy of quinapril in hypertensive patients with obesity. J Hypertens 1999; 17 (Suppl. 3): S294.
21. Larochelle P. Effect of quinapril on the albumin excretion rate in hatients with mild to moderate essential hypertension. Am J Hypertens 1996; 9: 551–9.
22. Dominguez LХ, Barbagallo M, Kattah W et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens 1995; 8: 808–14.
23. Чазова И.Е., Мычка В.Б. и др. Роль ИАПФ в лечении сахарного диабета типа 2: фокус на аккупро. Артериал. гипертензия (Репринт) 2003; 3–6.
24. Чазова И.Е., Мычка В.Б. и др. Эффективность квинаприла у больных с множественными факторами сердечно-сосудистого риска (результаты Российского, многоцентрового, рандомизированного исследования "ЭКО"). Кардиоваскул. тер. и профилакт. 2004; 3: 4–10.
2. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапии ингибиторами ангиотензинпревращающего фермента. Кардиология. 2001; 5: 100–4.
3. Ferrari R, Bachetti T, Guardigli G et al. Bradykinin and coronary artery disease. Eur Heart J 2000; 2 (Suppl. H): H14–H19.
4. Haefeli WE, Linder L, Lusher TF. Quinaprilat induces artepial vasodilation mediated by nitric oxide in humans. Hypertension 1997 Oct; 30 (4): 912–7.
5. Horing B, Arakawa N, Haussmann D et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98: 2842–8.
6. Anderson TJ, Elstein E, Haber H et al. Comparative stady of ACE-Inhibition, angiotensin II antagonism, and calsium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANFF Study). J Am Coll Cardiol 2000; 35: 60–6.
7. Maclean D. Quinapril: а double-blind, placebo-controlled trial in essential hypertension. J Vascular Dis 1989; 4: 370–81.
8. Parra-Carrillo Jose Z, Olvera S, Verdjeo J et al. Multicentric study of quinapril, an angiotensin converting enzyme inhibitor, in the treatment of mild to moderate essential hypertension. Curr Ther Res 1992; 51: 185–95.
9. Wadworth AN, Brogden RN. Quanapril: a revive of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs 1991; 41 (3): 378–99.
10. Parageorgiou A, Karayannis A, Athyros V et al. A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug invest 1994; 7 (1): 396–404.
11. Romero R, Castellote Е, Ocon J et al. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8.
12. Ienz Т, Schulte К-L, Wagner В et al. Quinapril, hydrochlorothiazide, and combination in patients with moderate со severe hypertension. Eur Heart J 1994; 15: 940–6.
13. Hausberg М. Angiotensin converting enzyme inhibitor versus beta- blocker for treatment of hypertension. 17'" scientific meeting ог 1йе international society of hypertension. 1998; 24.16.
14. Parageotgiou А, Karayiannts A, Athutos V et al. A comparative study of the efficacy and safety of quinapril and lisinopril in patients with mild to moderate hypertension. Drug Invest 1994; 7: 13–7.
15. Nakajima Т, Yamda Т, Setoguchi М. Quinapril provides more potent inhibition of tissue АСЕ than enalapril. J Cardiovasc Pharmacol 1992; 19: 102–7.
16. Kannel WВ. In: Left ventricular hypertrophy and regression. London: Messerrli 1992; 359: 1600–3.
17. Franz I-W, Tonnesmann U, Muller JF. Time course of complete regression of left ventricular hypertrophy during long-term antihypertensive therapy with АСЕ inhibitors. 8-th european meeting on hypertension. 1997; 100.
18. Clroux J. Endothelium: а new target for cardiovascular therapeutics. J Am Coll Cardiol 2000; 1: 67–70.
19. Мартынов А.И., Гороховская Г.Н. и др. Перспективы медикаментозного лечения эндотелиальной дисфункции. Фарматека. 2005; 9: 31–4.
20. Volkova N et al. Efficacy of quinapril in hypertensive patients with obesity. J Hypertens 1999; 17 (Suppl. 3): S294.
21. Larochelle P. Effect of quinapril on the albumin excretion rate in hatients with mild to moderate essential hypertension. Am J Hypertens 1996; 9: 551–9.
22. Dominguez LХ, Barbagallo M, Kattah W et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens 1995; 8: 808–14.
23. Чазова И.Е., Мычка В.Б. и др. Роль ИАПФ в лечении сахарного диабета типа 2: фокус на аккупро. Артериал. гипертензия (Репринт) 2003; 3–6.
24. Чазова И.Е., Мычка В.Б. и др. Эффективность квинаприла у больных с множественными факторами сердечно-сосудистого риска (результаты Российского, многоцентрового, рандомизированного исследования "ЭКО"). Кардиоваскул. тер. и профилакт. 2004; 3: 4–10.
Авторы
Г.Н.Гороховская, М.М.Петина, Е.В.Акатова, И.Г.Аксенов, А.И.Мартынов
Кафедра госпитальной терапии №1 МГМСУ
Кафедра госпитальной терапии №1 МГМСУ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.